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Abstract
Backgroud: Although propofol and dexmedetomidine have been widely used for monitored anesthesia care, their
adverse effects necessitate the search for better methods. Therefore, we performed this randomized controlled trial
to evaluate the combined use of propofol and dexmedetomidine.
Methods: Eighty-seven adult patients undergoing hand surgery under brachial plexus block were randomly
allocated to receive 1.6 μg/ml of the target effect site concentration of propofol (P group) and infusion of 0.4 μg/
kg/h dexmedetomidine following a loading dose of 1.0 μg/kg for 10 min (D group). The M group received a half-
dose of both drugs simultaneously. The maintenance dose was adjusted to maintain an Observer Assessment of
Alertness/Sedation score of 3. Cardiorespiratory variables, adverse effects, and drug efficacy were observed.
Results: The significantly higher mean arterial pressure (mmHg) in the D group [P group 86.9 (12.6), D group 96.0
(12.2), M group 85.6 (10.6), p = 0.004)] and a significantly higher heart rate (beat/min) in the P group were observed
[P group 67.3 (9.0), D group 57.8 (6.9), M group 59.2 (7.4), p < 0.001)]. The M group had a significant lower incidence
of airway obstruction (p < 0.001) and the D group had a higher incidence of bradycardia requiring atropine (p = 0.
001). The P group had higher incidences of hypoxia (p = 0.001), spontaneous movement (p < 0.001) and agitation
(p = 0.001). The satisfaction scores of the patients (p = 0.007) and surgeon (p < 0.001) were higher in the M group.
Onset time was significantly longer in the D group (p < 0.001).
Conclusions: The combined use of propofol and dexmedetomidine provided cardiovascular stability with
decreased adverse effects. Additionally, it led to a similar onset time of propofol and achieved higher satisfaction
scores.
Trial registration: KCT0001284. Retrospectively registered 25 November 2014.
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Background
Monitored anesthesia care (MAC) has been used to pro-
vide sedation, comfort, memory loss and relief from anx-
iety during therapeutic or diagnostic procedures with
sedation and analgesia [1, 2]. Because respiratory depres-
sion is associated with the most serious patient injuries
during MAC [3], the optimal state of MAC is the main-
tenance of sedation and normal cardiovascular functions
without severe respiratory depression and airway ob-
struction. The capability to rapidly modulate the depth
of sedation when necessary is also an important require-
ment of MAC. Several sedative, analgesics and narcotics
are used to achieve these objectives while minimizing
adverse effects.
Among these drugs, propofol provides antiemetic
properties, high quality sedation, and rapid onset and
recovery times [4, 5]. Additionally, a consistent target
effect site concentration can be maintained without
overdose of the drug through target controlled infusion
(TCI) technology [6]. Nevertheless, propofol has some
adverse effects such as severe respiratory depression and
hypotension, which highlight the need to find better
drugs for MAC [7, 8].
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Dexmedetomidine, a highly selective α2-adrenergic re-
ceptor agonist, has analgesic and sedative properties
without significant respiratory depression [9, 10]. Al-
though less significant respiratory depression is promin-
ent merits of dexmedetomidine, the adverse effects of
dexmedetomidine include a dose-dependent decrease in
blood pressure and heart rate due to its sympatholytic
effects [11, 12]. In the absence of an ideal sedative agent,
there is great interest in combining different agents to
maximize efficacy and minimize adverse effects, with
some studies finding that these combinations have sig-
nificant benefits over single agents [13, 14]. In this study,
we hypothesized that the combinatory use of propofol
and dexmedetomidine would reduce adverse effects such
as respiratory depression and cardiovascular depression
and improve efficacy as measured by early onset and re-
covery time. Therefore, we performed this prospective,
randomized, controlled double-blinded trial to evaluate




After approval by the Institutional Review Board (IRB)
of Hanyang University Hospital, Seoul, Korea, this study
was registered at http://cris.nih.go.kr (Clinical Research
Information Service, registration number: KCT0001284).
Adult patients between 20 and 75 years of age who were
scheduled for elective hand surgeries under brachial
plexus block were included in this randomized control
trial after obtaining written informed consent. Only pa-
tients who wanted sedation were included. Patients were
excluded if they met the following criteria: (1) American
Society of Anesthesiologists (ASA) physical status more
than IV; (2) impaired cognitive function; and (3) ob-
structive sleep apnea, neuropsychiatric, cardiovascular,
respiratory, renal or liver disorders.
Eligible patients were randomly assigned to three
groups and the sequence of the sedation procedure
was allocated by opening sealed envelopes before
monitoring the patients. These envelopes contained a
pre-determined group, which was randomly assigned
using a random number generator in the Excel pro-
gram by author (LHJ).
Study groups
There are three groups in this study. In the P group,
1.6 μg/ml of initial target effect site concentration (Ce)
of propofol (2% Fresofol®, Fresenius Kabi, Korea Ltd,
Korea) was infused through a TCI pump (Orchestra®
Base Primea, Fresenius Kabi, Brezins, France). For dose
maintenance, the propofol was titrated by 0.2 μg/ml of
Ce depending on the Observer Assessment of Alertness/
Sedation (OAA/S) score [15]. Patients in the D group
received an infusion of 0.4 μg/kg/h dexmedetomidine
(Precedex®, Hospira Inc., Lake Forest, USA) following a
loading dose of 1.0 μg/kg over 10 min. And then, the
dose of dexmedetomidine was adjusted by 0.08 μg/kg/h
according to the OAA/S score. In the M group, 0.8 μg/
ml of initial Ce of propofol was infused through an Or-
chestra® Base Primea TCI pump and a loading dose of
dexmedetomidine of 0.5 μg/kg was infused over 10 min
together. Then, 0.2 μg/kg/h dexmedetomidine was in-
fused for the maintenance dose. During the sedation, the
maintenance doses of propofol and dexmedetomidine
were titrated by the same proportion depending on the
OAA/S score. The dose of propofol was adjusted by
0.2 μg/ml of Ce and the dose of dexmedetomidine was
adjusted by 0.04 μg/kg/h simultaneously. The mainten-
ance dose of each group was adjusted by one of the au-
thors to maintain the OAA/S score of 3 in all study
groups.
Study protocol
Brachial plexus block was conducted using the same pre-
defined protocol without premedication. All anesthetic
procedures and surgeries were performed by the same
anesthesiologist and surgical team. After arrival to the
operating room, the patient’s vital signs were monitored
by noninvasive blood pressure measurement, electrocardi-
ography, and pulse oximetry. Respiratory variables such
as end-tidal CO2 and respiratory rate were monitored by
a side-stream infrared gas analyzer (Drager-VAMOS®,
Drager Medical, Lubeck, Germany). Supplemental
oxygen (4 L/min) was given to all patients. The axillary
brachial plexus block was performed with 0.75% ropiva-
caine 20 ml under ultrasound-guided techniques. After
adequate surgical anesthesia has been achieved, patients
received a sedative in accordance with the method
above. During sedation, all patients were maintained in
the supine position and the sedation statuses of the pa-
tients were evaluated by the OAA/S score and bispectral
index (BIS) monitoring. All unnecessary noise was mini-
mized during sedation.
Assessment of drug effect
The primary endpoints were the changes of mean arter-
ial pressure and the extent of airway obstruction (1 = pa-
tent airway, 2 = airway obstruction alleviated by jaw
thrust, 3 = airway obstruction relieved by positive mask
ventilation). The time to achieving the target depth of
sedation (OAA/S score of 3) was measured by calculat-
ing the time from injection to an OAA/S score of 3. In
addition, the time to achieving BIS score of 70 was also
measured. During the sedation procedure, vital signs
and sedation status including OAA/S scores, BIS scores,
mean arterial pressure, heart rate, SpO2, end-tidal CO2
and respiratory rate were recorded at the following
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times: (1) before the injection of the drug (T0); (2)
5 min after infusion (T1); (3) achieving the target mental
status (OAA/S score 3) (T2); (4) 15 min after achieving
the target mental status (T3); (5) 30 min after achieving
the target mental status (T4); (6) termination of infusion
(T5); and (7) an alert mental status (T6).
In addition to the occurrence of airway obstruction,
the incidence of adverse events such as hypoxia (SpO2 <
90% for > 10 s), spontaneous movements, cough, nausea,
vomiting, agitation, and the administration of atropine
and ephedrine were also assessed. In cases with a heart
rate < 45 beats/min or a more than 30% decrease in
mean arterial pressure from baseline values, 0.5 mg atro-
pine and 5 mg ephedrine were used, respectively. Spon-
taneous movements were recorded when movements of
the upper or lower extremity occurred more than three
times. Agitation was defined as non-cooperative and
non-purposeful motor restlessness. The total dose of in-
fused drug and the recovery time from the termination
of injection to an OAA/S score of 5 and BIS score of 90
were also measured. To compare the dose rates of the
infused drugs, we used the value of the total dose of
infused drug per body weight and infusion time. After
surgery, the incidence of awareness and recall during
sedation was examined. The satisfaction of the patients
and surgeon, blinded to group assignment, was evalu-
ated using a visual analog scale (VAS) of 0 to 100. All
data were assessed by another anesthesiologist who was
blinded to group assignment.
Justification of sample size and Statistical analysis
According to a previous study that compared the effect-
iveness of dexmedetomidine and propofol target-
controlled infusion for sedation [16], mean arterial pres-
sure of propofol was 94.7 mmHg with a standard devi-
ation of 12.3 mmHg. We considered 11 mmHg to be a
meaningful difference and the calculated sample size
was 27 patients in each group with an assumed an α
error of 5% and ß error of 10%. Accounting for a drop-
out rate of 5%, 30 patients were allocated to each group.
Categorical data were expressed as numbers of pa-
tients (percentages as appropriate) and compared using
Pearson’s chi-square test with Fisher’s exact test. Con-
tinuous data were expressed as mean (standard devi-
ation). After a normality test was performed using the
Shapiro-Wilk test, continuous data was compared using
one-way analysis of variance (ANOVA) and a post hoc
test (Duncan). Other data was analyzed by the Kruskal-
Wallis test with the Mann-Whitney U-test, and p values
were adjusted with Bonferroni’s correction. Repeated
measures ANOVA was used to compare hemodynamic
and respiratory variables over time and the incidence of
adverse events was analyzed using the Chi-square test
with adjusted p values by Bonferroni’s correction.
Statistical analysis was performed with SPSS software
(version 21.0 SPSS Ins., Chicago, USA). P < 0.05 was
considered statistically significant.
Results
Among 157 patients who were assessed for eligibility
from August 2014 until August 2015, 67 patients were
excluded because of not meeting the inclusion criteria or
declining to participate. As a result, 90 patients were
randomly assigned to each group by a predefined
method. In P group, two patients showed so excessive
agitation that general anesthesia was needed and in D
group, one patient was excluded from analysis because
the sedation level of the patient was deeper than the
designated state per our protocol. Consequently, the
data from 87 patients were analyzed in this study (Fig. 1).
Patient demographic data are summarized in Table 1
and there were no differences in patient characteristics
between the three groups.
Changes in hemodynamic and respiratory variables
The reduction of mean arterial pressure (mmHg) in the
D group was significantly less than other groups [P group
86.9 (12.6), D group 96.0 (12.2), M group 85.6 (10.6), p =
0.004)] (Fig. 2a) and the reduction of heart rate (beat/
min) in the P group was significantly less than other
groups [P group 67.3 (9.0), D group 57.8 (6.9), M group
59.2 (7.4), p < 0.001)] (Fig. 2b). Although there were no
differences in end-tidal CO2 (p = 0.56) (Fig. 2d) and re-
spiratory rate (p = 0.38) (Fig. 2e) between groups, the P
group had a significantly lower SpO2 (p < 0.001) (Fig. 2c).
Adverse events
There was a significant lower incidence of the extent
of airway obstruction (p < 0.001) in the M group
(Table 2). The P group had a higher incidence of
hypoxia (p = 0.001), spontaneous movement (p < 0.001)
and agitation (p = 0.001) than other groups. The inci-
dence of bradycardia requiring atropine was signifi-
cantly greater in the D group (p = 0.001). No episodes
of nausea, vomiting, or hypotension were found and
there were no differences in the occurrence of cough
(p = 0.16) between groups.
Onset and recovery time and dose rate of drug infusion
Although there was a significantly longer time (seconds)
to achieve the target depth of sedation in the D group [P
group 502.7 (149.5), D group 709.1 (106.0), M group
538.9 (81.1), p < 0.001)], there was no difference in re-
covery time among the groups (p = 0.07) (Table 3). The
dose rate of propofol infusion in the P group and of dex-
medetomidine infusion in the D group were 3.54 (1.01)
mg/kg/h and 1.26 (0.37) μg/kg/h, respectively. In total,
1.59 (0.56) mg/kg/h of propofol and 0.61 (0.17) μg/kg/h
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of dexmedetomidine were infused in the M group. In
comparison with the half-dose of drug infusion in the P
and D groups, there were no differences in the dose
rates of drug infusion.
The incidence of awareness and the degree of satisfaction
There were no incidences of awareness and recall during
sedation among the three groups. The higher VAS score
of patient satisfaction was found in M group [P group
90.0 (7.9), D group 89.2 (9.2), M group 95.0 (4.7), p =
0.007] and the VAS score of surgeon satisfaction was
significantly different in each group [P group 81.0 (10.4),
D group 87.3 (8.1), M group 93.7 (5.9), p < 0.001)]
(Table 3).
Discussion
We performed this randomized, controlled, double-
blinded trial to evaluate the efficacy and safety of the
combinatory use of propofol and dexmedetomidine at
half of their usual doses. Our study demonstrated that
the combinatory use of propofol and dexmedetomidine
provided cardiovascular stability, early onset time and
higher satisfaction scores without delayed recovery time
and adverse effects such as airway obstruction, hypoxia,
and spontaneous movement.
According to our study, the reduction of mean ar-
terial pressure in the D group was significantly less
than other groups, and mean arterial pressure actually
rather increased 5 min after infusion (Fig. 2a). The
rapid injection of a loading dose of dexmedetomidine
can have biphasic effects on blood pressure, with
temporary increases in blood pressure by a direct α2-
adrenoceptor-induced vasoconstrictive response in the
peripheral vasculature followed by a lower mean
Fig. 1 Flow diagram of patient recruitment and exclusion criteria for the study







Age (years) 45.5 (14.3) 47.8 (15.2) 49.6 (18.1)
Male sex 15 (53.6) 11 (37.9) 10 (33.3)
Height (cm) 166.8 (9.5) 163.8 (9.0) 164.5 (9.4)
Weight (kg) 64.0 (12.0) 61.7 (9.9) 60.3 (10.2)
Body mass index
(kg/m2)










116.3 (30.6) 126.7 (43.1) 110.7 (33.5)
Hypertension 2 (7.1) 6 (20.7) 3 (10)
Values are numbers of patients (%), or mean (standard deviation)
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arterial pressure due to decreased sympathetic outflow
[9, 12]. This biphasic trend in blood pressure was ob-
served in the D group, but temporary increases of
blood pressure were not observed in the M group. In
terms of heart rates, dexmedetomidine can cause
bradycardia due to its well-known sympatholytic effects
[12, 17, 18]. The heart rates in both the P and M groups
were decreased after infusion. However, considering that
the D group required the frequent use of atropine (27.6%)
to maintain heart rates, while the M group did not require
atropine, it is clear that the combination of propofol and
dexmedetomidine helped maintain heart rates. After
taking these results into consideration, we suggest that the
combination of propofol and dexmedetomidine provided
cardiovascular stability.
As described above, respiratory depression is the most
significant adverse effect during MAC [3]. Unlike propo-
fol, in which the incidence rate of hypoxemia was re-
ported to be 11% [7], sedation with dexmedetomidine
has a mechanism similar to natural sleep with hyperpo-
larization of norepinephrine receptors in the locus cere-
leus [19]. The locus cereleus plays an essential part in
regulating sleep and the modulation of respiratory con-
trols [20]. Therefore, the effects of dexmedetomidine on
respiration and ventilation are minimal and several pre-
vious studies already have revealed the minimal changes
in respiratory variables such as oxygen saturation, arterial
carbon dioxide, respiratory rates and arterial pH [9, 21,
22]. Similar to the results of these studies, oxygen satur-
ation in the D group was significantly higher than in the P
group. However, as the depth of sedation increases, dex-
medetomidine can cause indirect respiratory depression
due to respiratory obstruction from the relaxation of
the pharyngeal muscle tone [23]. This obstruction,
which results in apnea, is resolved by applying slight
jaw thrust. Because relatively deep sedation was main-
tained in our study, the incidence of airway obstruc-
tion and hypoxia was similar between the P and D
Fig. 2 Cardiorespiratory variables during sedation. a Mean arterial pressure (MAP) in mmHg. b Heart rate (HR) in beats per minute. c Pulse
oximetry (SpO2) in percentage. d End-tidal CO2 in mmHg. e Respiratory rate (RR) in number of respirations per minute. All data are presented as
mean and standard error. *: P < 0.05 compared to the P group, †: P < 0.05 compared to the D group
















Hypoxia 12(42.9) 4 (13.8)* 1(3.3)* 0.001
Spontaneous
movement
10 (35.7) 1 (3.4)* 0 (0)* <0.001
Cough 5 (17.9) 3 (10.3) 1(3.3) 0.16
Nausea 0 (0) 0 (0) 0 (0) 1.00
Vomiting 0 (0) 0 (0) 0 (0) 1.00
Agitation 6 (21.4) 0 (0)* 0 (0)* 0.001
Bradycardia
requiring atropine
1 (3.6) 8 (27.6)* 0 (0)† 0.001
Hypotension
requiring ephedrine
0 (0) 0 (0) 0 (0) 1.00
Values are numbers of patients (%)
*P < 0.05 compared to the P group, †P < 0.05 compared to the D group
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groups. Despite the equivalent sedation levels of the other
groups, our study revealed that the combination of propo-
fol and dexmedetomidine resulted in a significantly lower
incidence of airway obstruction and hypoxia.
In order to avoid transient hypertension, the slow in-
jection of dexmedetomidine was required [10], which
can result in slower onset of sedation. The time to
OAA/S 3 or BIS 70 of the D group, which was longer
than the other groups by about 3 min, also implies the
delayed onset of sedation for dexmedetomidine, which
correlates well with the results of a previous study [11].
The combined use of propofol and dexmedetomidine
overcomes this limitation and results in an onset time
similar to that of propofol. As the recovery time from
sedation with dexmedetomidine and propofol are known
to be equivalent [18, 24], there were no differences in re-
covery time between the three groups.
Our study also showed that patients and surgeons were
more satisfied with the combined use of propofol and dex-
medetomidine. Patients in the P group felt discomfort
during the injection of propofol while those in the D
group experienced a slower onset of dexmedetomidine.
Surgeon satisfaction was significantly different between
groups. The lowest satisfaction in the P group was due to
the high incidence of agitation and spontaneous move-
ment. Spontaneous movement caused by propofol injec-
tion, with rates of 5.5 to 22%, correlates with imbalances
in excitatory inhibitory neurotransmitters [25–27]. Be-
cause spontaneous movement during procedures under
MAC cancompromise patient safety, a low incidence of
spontaneous movement closely related not only with
safety, but also with a smoother procedure due to less fre-
quent interruptions. Similar to patient satisfaction, the
slower onset of dexmedetomidine was the reason why sur-
geon satisfaction scores in the D group were lower than in
the M group. The high level of surgeon satisfaction in the
M group was observed because of the early onset time
and the absence of other complications.
Our study has several limitations. First, although one
of the advantages of dexmedetomidine is its analgesic
property [9–11, 28], we could not evaluate its analgesic
effects because this study was conducted under brachial
plexus block. Therefore, further studies are needed to
evaluate the analgesic effect when dexmedetomidine is
used in combination with propofol. Another limitation is
that we did not use premedication, which could have an
influence on sedation level. Anxiety due to the unfamil-
iar operating room environment and undergoing regional
anesthesia could have increased baseline blood pressure,
heart rate and respiratory rate. Lastly, the accuracy of end-
tidal CO2 monitoring is also a limitation. Although we
placed the airway adapter as close as possible to the
patient’s airway, some degree of measurement error of
end-tidal CO2 is inevitable in non-intubated patients.
We expected a synergistic effect between propofol and
dexmedetomidine. However, judging from the require-
ment of half of the usual doses of propofol and dexme-
detomidine to maintain the target sedation level, the
combined use of propofol and dexmedetomidine seemed
to have an additive effect. Further studies are needed to
accurately assess whether the combined use of propofol
and dexmedetomidine has an additive effect or not.
Conclusions
We conclude that the combination of propofol and dex-
medetomidine provided cardiovascular stability without
transient hypertension and bradycardia. The combin-
ation of these two agents also improved patient safety by
decreasing the incidence of airway obstruction, hypoxia,
spontaneous movement and agitation during deep
Table 3 Comparison of onset and recovery time, dose rate of drug infusion, and satisfaction scores
Variable P group (n = 28) D group (n = 29) M group (n = 30) P value
Onset time (seconds)
Time to OAA/S score 3 502.7 (149.5) 709.1 (106.0)* 538.9 (81.1)† <0.001
Time to BIS 70 590.3 (146.8) 809.3 (106.7)* 621.1 (96.0)† <0.001
Recovery time (seconds)
Time to OAA/S 5 478.8 (178.4) 580.9 (178.1) 495.5 (178.8) 0.07
Time to BIS 90 585.2 (188.4) 682.0 (179.2) 585.9 (188.6) 0.08
Dose rate of drug infusion
Propofol (mg/kg/h) 3.54 (1.01) 1.59 (0.56)
Dexmedetomidine (μg/kg/h) 1.26 (0.37) 0.61 (0.17)
Patient satisfaction score (VAS) 90.0 (7.9) 89.2 (9.2) 95.0 (4.7)*† 0.007
Surgeon satisfaction score (VAS) 81.0 (10.4) 87.3 (8.1)* 93.7 (5.9)*† <0.001
Values are mean (standard deviation)
OAA/S score Observer Assessment of Alertness/Sedation score, BIS bispectral index, VAS visual analog scale
*P < 0.05 compared to the P group, †P < 0.05 compared to the D group
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sedation. In addition, the use of propofol and dexmede-
tomidine had a similar onset time as that of propofol
without a delayed recovery time, and achieved higher
satisfaction scores than with the use of a single drug.
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